|
|
 |
|
Viewing report
|
|
|
|
Commercial and Pipeline Insight: Opioids - Short Acting and Anti-abuse Technologies Set to Fragment and Grow the Market
Datamonitor, March 2008, Pages: 233
The opioid market is currently valued at $7.7 billion and is set to increase over the next 10 years at a CAGR of 2.4%. Despite this market being exclusively comprised of old genericized molecules, novel formulations and delivery methods have stimulated growth over the last 5 years. This growth is set to continue as current market players instigate lifecycle management strategies to retain value.
Scope
- Sales volume and value forecasts to 2017 of marketed brands, generics, and key late-stage pipeline drugs.
- Analysis of patient potential, unmet needs and clinical trial design in the opioid market.
- Overview of key marketed brands, late- and early-stage pipeline drugs.
- Identification of future market events that are expected to affect opioid revenues.
Highlights of this title
Short-acting opioids represent good in-licensing opportunities for companies with large sales and marketing resources. This market is expected to triple in value over the next 10 years, driven by Cephalons Fentora for use in breakthrough pain, and supported by other new short-acting fentanyl formulations.
The long-acting opioid market was valued at over $3 billion in 2007, and is due to grow until the patent expiry of market leader OxyContin in 2011. After a short lived decline, market growth will be stimulated by the launch of anti-abuse formulations, a technical development anticipated to create a $1 billion market.
The topical market represents an opportunity for companies to enter a comparatively underserved market. Although Johnson and Johnsons market leading Duragesic (fentanyl patch) has faced generic opposition since 2005, sales remain relatively strong due to brand strength and the lack of branded competition.
Key reasons to purchase this title
- Benchmark key late-stage pipeline opioids against current market leading brands.
- Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands.
- Understand unmet needs and opportunities in the opioid market based on key opinion leader comments.
Customers who bought this item also bought
Forecast Insight: Opioids - Saturation limits the commercial potential of individual brands
Commercial Insight: Pain Market Overview - Non-traditional Analgesics and Opioid Reformulations to Sustain Sector Growth
US Cancer Pain Report
Strategic Perspective 2001: Opioid Use in Pain Management
Pain Therapeutics - Drugs, Markets and Companies
Pipeline Insight: Breakthrough Pain - Fast-Acting Players will Capture Majority Market Share
Commercial Insight: Targeted Therapy Cancer Brands - High Growth Market will see Eight New Blockbusters by 2017
Opioids Market Forecast
Commercial Insight: CNS Market Overview - Commercial Dynamics And Outlook Of The Neurology, Pain And Psychiatry Market Sectors
U.S. Opioid and Non-Opioid Pain Management Pharmaceuticals Markets
Pipeline and Commercial Insight: Alzheimers Disease - Scenario Forecasts Reveal Vast Market Potential
Pipeline Insight: Neuropathic Pain - Emerging Drugs Fail to Capitalize in Lucrative Market
|
|
|
|
